Novel valproate half-sandwich rhodium and iridium conjugates to fight against multidrug-resistant Gram-positive bacteria-Reference-Cited by-同舟云学术

Novel valproate half-sandwich rhodium and iridium conjugates to fight against multidrug-resistant Gram-positive bacteria

Published:2023 Issue:38 Volume:52 Page:13482-13486
ISSN:1477-9226
Container-title:Dalton Transactions
language:en
Short-container-title:Dalton Trans.

Author:

Marco Alicia¹^ORCID,Vigueras Gloria¹^ORCID,Busto Natalia²³^ORCID,Cutillas Natalia¹,Bautista Delia⁴,Ruiz José¹^ORCID

Affiliation:

1. Departamento de Química Inorgánica, Universidad de Murcia, and Biomedical Research Institute of Murcia (IMIB-Arrixaca), E-30100 Murcia, Spain

2. Departamento de Química, Facultad de Ciencias, Universidad de Burgos, Plaza Misael Bañuelos s/n, E-09001, Burgos, Spain

3. Departamento de Ciencias de la Salud. Facultad de Ciencias de la Salud. Universidad de Burgos, Hospital Militar, Paseo de los Comendadores, s/n, 09001 Burgos, Spain

4. SUIC-ACTI, Universidad de Murcia, E-30100 Murcia, Spain

Abstract

The valproic acid conjugation to Ir(iii) and Rh(iii) half-sandwich complexes seems to switch on their antibacterial activity towards Enterococcus faecium and Staphylococcus aureus Gram-positive bacteria.

Funder

Ministerio de Ciencia e Innovación

Agencia Estatal de Investigación

“la Caixa” Foundation

Universidad de Murcia

Fundación Séneca

Consejería de Educación, Junta de Castilla y León

Publisher

Royal Society of Chemistry (RSC)

Subject

Inorganic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/DT/D3DT01678A

Reference39 articles.

1. I. A.Joshua , M.Bobai and C. S.Woje , in The Global Antimicrobial Resistance Epidemic , ed. G. Tellez-Isaias , IntechOpen , Rijeka , 2022 , ch. 4

2. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

3. Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections

4. World Health Organization , 2019 antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline , World Health Organization , Geneva , 2019